Business / Finance

RSS

YM BioSciences prices 35,000,000 common shares in underwritten public offering

YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer related products, today announced the pricing of 35,000,000 common shares at US$2.00 per common share in its previously announced underwritten public offering.

24 Feb 2012

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011.

24 Feb 2012

Cyberonics third quarter net sales increase 16% to $54.5 million

Cyberonics, Inc. today announced results for the quarter ended January 27, 2012.

24 Feb 2012

Biofund, Quintiles to expand clinical development services in Russia

Russian Venture Company Biofund, a Russian-based investment firm, and Quintiles, the world's leading biopharmaceutical services company, today announced a definitive agreement to support expansion of clinical development services within the Russian Federation, the world's ninth most populous country.

24 Feb 2012

Western Dental Services celebrates expansion into Northern California

Western Dental Services, Inc., celebrates its continuing expansion into Northern California with a ribbon-cutting ceremony on Tuesday, February 28th, at its newest office in Livermore.

24 Feb 2012

Aerocrine net sales increase 10% to SEK 93.5m for January - December 2011

Aerocrine: January - December 2011. Global Net sales grew by 10% to SEK 93.5m (84.7). Adjusted for currency fluctuations, net sales rose by 18%.

24 Feb 2012

Sandvik reaches agreement with Orchid to sell medical solutions unit

Sandvik has reached an agreement with Orchid Orthopedic Solutions (Orchid), owned by Altor Fund III, to divest Sandvik Medical Solutions, a unit within the Sandvik Venture business area with contract manufacturing of medical implants and instruments for orthopaedic and dental applications.

24 Feb 2012

ValueOptions, LifeWIRE partner to create mobile monitoring, intervention and counseling program

ValueOptions, the nation's largest independent behavioral health and wellness company, and LifeWIRE announced today a joint teaming agreement to create a mobile monitoring, intervention and counseling program.

23 Feb 2012

Medivir reports net sales of SEK 698.6M for fiscal 2011

Today, Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January - 31 December and its operational report for the fourth quarter of 2011.

23 Feb 2012

ANFP renames and re-launches its charitable foundation

As a part of its recently announced strategic rebranding initiative, the Association of Nutrition & Foodservice Professionals (ANFP) has renamed and re-launched its charitable foundation.

23 Feb 2012

Roche grants in vitro diagnostics product license for real-time PCR technology to LTC

Roche and Life Technologies Corporation announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.

23 Feb 2012

Healthcare Realty Trust reports total revenues of $76.4M for fourth quarter 2011

Healthcare Realty Trust Incorporated today announced results for the fourth quarter ended December 31, 2011. Normalized FFO for the three months ended December 31, 2011 totaled $0.33 per diluted common share.

23 Feb 2012

Onyx reports total operating revenue of $237.0M for fourth quarter 2011

Onyx Pharmaceuticals, Inc. today reported its financial results for the full year and fourth quarter 2011. Onyx reported non-GAAP net income of $42.0 million, or $0.66 per diluted share, for the full year 2011 compared to non-GAAP net income of $39.2 million, or $0.63 per diluted share, for the same period in 2010.

23 Feb 2012

Express Scripts fourth quarter gross profit increases 8% to $0.9 billion

Express Scripts, Inc. announced 2011 fourth quarter and full year net income from continuing operations of $290.4 million and $1,275.8 million, or $0.59 and $2.53 per diluted share, respectively.

23 Feb 2012

Volcano fourth quarter revenues increase 14% to $92.7 million

Volcano Corporation, a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today said revenues in the fourth quarter of 2011 increased 14 percent versus the fourth quarter of 2010.

23 Feb 2012